연구동향 분석
박사

Influence of Pharmacogenomic Factors and Smoking Status on the Pharmacokinetics of Tolperisone

이윤정 2015년

논문상세정보
인용/피인용
' Influence of Pharmacogenomic Factors and Smoking Status on the Pharmacokinetics of Tolperisone' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • cyp1a2
  • cyp2c19
  • cyp2d6
  • genetic
  • pharmacogenomics
  • tolperisone
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
65 0

0.0%

' Influence of Pharmacogenomic Factors and Smoking Status on the Pharmacokinetics of Tolperisone' 의 참고문헌

  • de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal Biol Chem. 1994b;269(22):15419-22.
  • de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994a;46(4):594-8.
  • Zuo LJ, Guo T, Xia DY, Jia LH. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers. 2012;16(2):102-8.
  • Vora A. Tolperisone. Journal Assoc Physicians India. 2010;58:127-8.
  • Tantcheva-Po r I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131-44.
  • Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-13.
  • Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-23.
  • Ribi C, Vermeulen C, Hauser C. Anaphylactic reactions to tolperisone (Mydocalm). Swiss Med Wkly. 2003;133:369-71.
  • Quasthoff S, M ckel C, Zieglg nsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008;14(2):107-19.
  • Pawlowska M, Bogiel M, Duda J, Sieradzki E. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. Eur Journal Clin Pharmacol. 2015;71(6):699-705.
  • Oishi M, Chiba K, Malhotra B, Suwa T. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010;38(9):1456-63.
  • Miskolczi P, Vereczkey L, Frenkl R. Gas-liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studies. Journal Pharm Biomed Anal. 1987(7);5:695-700.
  • Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther. 2001;70(6):552-60.
  • Martos V, Hofer KE, Rauber-L thy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A. Acute toxicity profile of tolperisone in overdose: Observational poison centre-based study. Clin Toxicol (Phila). 2015;53(5):470-6.
  • Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226(2):327-38.
  • Kwaśniewski A, Korbuszewska-Gontarz B, Mika S. Mydocalm causing anaphylaxis. Pneumonol Alergol Pol. 2003;71(5-6):250-2.
  • Kocsis, P. Farkas S, Fodor L, Bielik N, Th n M, Kolok S, Gere A, Csejtei M, Tarnawa I. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. Journal Pharmacol Exp Ther. 2005;315(3):1237–46.
  • Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br Journal Clin Pharmacol. 2000;49(4):343-51.
  • Karaźniewicz-Łada M, Danielak D, Rubiś B, Burchardt P, Oszkinis G, Gł wka F. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Journal Clin Pharmacol. 2014;54(8):874-80.
  • Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 1996;6(4):351-5.
  • Jin SK, Chung HJ, Chung MW, Kim JI, Kang JH, Woo SW, Bang S, Lee SH, Lee HJ, Roh J. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. Journal Clin Pharm Ther. 2008;33(5):567-73.
  • Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
  • Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496-526.
  • Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412-20.
  • Gl ck J, Rymarczyk B, Rogala B. An immediate hypersensitivity reaction caused by tolperisone hydrochloride. Journal Investig Allergol Clin Immunol. 2011;21(5):411-2.
  • Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur Journal Clin Pharmacol. 2012;68(9):1267-74.
  • Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther. 2007;11(3):171-81.
  • Furuta Y, Yoshikawa A. Reversible adrenergic alpha-receptor blocking action of 2,4’-dimethyl-3-piperidino-propiophenone (tolperisone). Jpn Journal Pharmacol. 1976;26: 543-50.
  • Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178-84.
  • Dulin J, Kov cs L, Ramm S, Horvath F, Ebeling L, Kohnen R. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 1998;31(4):137-42.
  • Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-58.
  • Dalmadi B, Leibinger J, Szeber nyi S, Borb s T, Farkas S, Szombathelyi Z, Tihanyi K. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003;31(5):631-6.
  • Choi CI, Park JI, Lee HI, Lee YJ, Jang CG, Bae JW, Lee SY. Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application. Journal Chromatogr B Analyt Technol Biomed Life Sci. 2012;911:59-63.
  • Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. Journal Clin Psychopharmacol. 2014;34(1):139-42.
  • Choi CI, Bae JW, Jang CG, Lee SY. Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype. Journal Clin Pharmacol. 2012;52(12):1934-8.
  • Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY. Considerable interindividual variation in the pharmacokinetics of tolperisone HCl. Int Journal Clin Pharmacol Ther. 2007;45:110-3.